Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer. (24th May 2017)

• Record Type: Journal Article
• Authors: Clinton, Timothy N.; Woldu, Solomon L.; Raj, Ganesh V.
• Is Part Of: Expert opinion on pharmacotherapy. Volume 18:Number 8(2017)
• Page Start: 825
• Page End: 832
• Publication Date: 2017-05-24
• Subjects: Degarelix -- androgen deprivation therapy -- LHRH agonist -- GnRH antagonist -- prostate cancer; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2017.1328056
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Androgen deprivation therapy (ADT) is the mainstay for advanced, hormone-sensitive prostate cancer, and options include surgical castration, luteinizing hormone-releasing hormone (LHRH) agonist, and more recently, gonadotropin releasing hormone (GnRH) antagonist therapy. Our understanding of the mechanisms and adverse effects of ADT has increased substantially, including the class-specific adverse effects of ADT. Areas covered : This review will summarize the pharmacodynamic and pharmacokinetic properties of the GnRH antagonist degarelix and its role in the management of advanced prostate cancer, the clinical evidence supporting its regulatory approval, as well as potential benefits and disadvantages over traditional LHRH agonist therapy. Expert opinion : Degarelix represents a newer class of ADT that results in a rapid and reliable decline in serum testosterone, a quality that makes it particularly advantageous in men presenting with symptomatic, hormone-sensitive prostate cancer. Due to differences in mechanism of action, there is observational data suggesting a potential cardiovascular and even oncologic benefit over traditional LHRH agonist therapy. Further research is ongoing to more clearly define this potential benefit.